A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO).
Phase of Trial: Phase I
Latest Information Update: 27 Aug 2014
At a glance
- Drugs Solifenacin (Primary)
- Indications Detrusor instability
- Focus Pharmacokinetics
- Sponsors Astellas Pharma BV
- 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2012 Additional trial locations (United Kingdom, USA) identified as reported by EudraCT.
- 24 Feb 2012 Additional trial locations added as reported by ClinicalTrials.gov.